tiprankstipranks
Trending News
More News >
Glow LifeTech (TSE:GLOW)
:GLOW
Advertisement

Glow LifeTech (GLOW) AI Stock Analysis

Compare
4 Followers

Top Page

TSE:GLOW

Glow LifeTech

(GLOW)

Select Model
Select Model
Select Model
Neutral 42 (OpenAI - 4o)
Rating:42Neutral
Price Target:
C$0.00
▼(-100.00% Downside)
Glow LifeTech's overall stock score is primarily impacted by its financial performance, which shows strong revenue growth but significant profitability challenges. Technical analysis indicates a bearish trend, and valuation metrics reflect ongoing losses. The absence of earnings call data and corporate events means these factors do not influence the score.

Glow LifeTech (GLOW) vs. iShares MSCI Canada ETF (EWC)

Glow LifeTech Business Overview & Revenue Model

Company DescriptionGlow Lifetech Corp., a biotechnology company, focuses on producing nutraceutical and cannabinoid-based products in North America. The company engages in the commercialization of two technologies, such as MyCell Enhanced technology, a nutraceutical and cannabis nutrient delivery technology; and a cannabis Smart Consumption System to assist users and patients to store, journal, control, consume, and manage cannabis related products. The company has the exclusive North American rights for the production, sale, and distribution rights for the certain micellization technology for cannabis and hemp derived ingredients, curcumin, vitamin K, and iron. It also engages in the business of secondary processing of ingredients to produce micellized materials from certain vitamins, nutraceuticals, and cannabis extracts that makes fat-soluble substances available for immediate absorption into the body reach near 100% bioavailability and water compatibility. The company was incorporated in 2018 and is based in Toronto, Canada.
How the Company Makes MoneyGlow LifeTech generates revenue through multiple streams, primarily from the sale of its health supplements and skincare products through both online and offline retail channels. The company operates a direct-to-consumer e-commerce platform, which allows it to capture higher margins by selling directly to customers. Additionally, GLOW has established partnerships with various health and wellness retailers, providing its products in physical stores and expanding its market reach. The company also engages in subscription-based models for certain product lines, ensuring consistent revenue flow. Furthermore, GLOW invests in research and development to innovate new products, which can lead to increased sales and market share, thereby enhancing its financial performance.

Glow LifeTech Financial Statement Overview

Summary
Glow LifeTech is experiencing strong revenue growth, but profitability remains elusive with significant net losses. The balance sheet shows a low debt burden, but the company struggles with negative equity returns. Cash flow challenges persist, indicating a need for improved operational efficiency and cost management to achieve sustainable profitability.
Income Statement
35
Negative
Glow LifeTech has shown significant revenue growth of 51.4% in the latest year, which is a positive indicator. However, the company is still operating at a loss with a negative net profit margin of -317.75% and negative EBIT and EBITDA margins. The high gross profit margin of 70.68% suggests potential for profitability if operational efficiencies improve.
Balance Sheet
40
Negative
The company's debt-to-equity ratio is relatively low at 0.16, indicating manageable debt levels. However, the negative return on equity of -103.37% highlights significant losses relative to shareholder equity. The equity ratio of 69.06% suggests a strong equity base compared to total assets, but overall financial health is weakened by persistent losses.
Cash Flow
30
Negative
Glow LifeTech's cash flow situation remains challenging with negative operating cash flow and free cash flow. The free cash flow to net income ratio is slightly positive at 1.01, indicating that free cash flow covers net income losses. However, the negative operating cash flow to net income ratio reflects ongoing cash burn issues.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.45M836.19K43.93K0.000.000.00
Gross Profit696.10K591.00K-759.18K-263.26K-43.39K0.00
EBITDA-1.28M-1.24M-1.31M-1.92M-4.59M-153.00K
Net Income-2.62M-2.66M-1.59M-2.24M-11.31M-153.00K
Balance Sheet
Total Assets3.69M3.72M1.91M2.31M3.76M2.60K
Cash, Cash Equivalents and Short-Term Investments1.06M1.29M34.0075.19K746.02K1.80K
Total Debt486.27K404.08K171.75K147.36K39.93K6.40K
Total Liabilities1.42M1.15M2.35M1.14M328.03K315.57K
Stockholders Equity2.26M2.57M-433.12K1.16M3.44M-312.97K
Cash Flow
Free Cash Flow-1.10M-1.36M-490.86K-1.36M-3.62M-18.65K
Operating Cash Flow-1.06M-1.35M-417.26K-1.30M-3.18M-18.65K
Investing Cash Flow-31.79K16.70K-60.91K18.31K-541.41K-1.36K
Financing Cash Flow1.79M2.62M445.01K491.44K4.59M2.93K

Glow LifeTech Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.05
Price Trends
50DMA
0.05
Negative
100DMA
0.05
Negative
200DMA
0.06
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
47.13
Neutral
STOCH
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GLOW, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.13 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:GLOW.

Glow LifeTech Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
C$15.41M-175.45%-3.93%-575.24%
42
Neutral
C$8.54M-250.28%327.55%21.37%
42
Neutral
C$6.65M-813.02%
29
Underperform
$7.29M25.09%
21
Underperform
$9.87M26.73%85.61%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:GLOW
Glow LifeTech
0.05
>-0.01
-16.67%
TSE:IOT
Innovotech
0.22
0.08
57.14%
TSE:KNE
Kane Biotech
0.04
-0.08
-66.67%
TSE:BLAB
Britannia Life Sciences Inc
0.10
0.00
0.00%
TSE:BETR
BetterLife Pharma
0.07
-0.05
-43.48%
TSE:BIOV
BioVaxys Technology
0.25
-0.30
-54.55%

Glow LifeTech Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Glow LifeTech Strengthens Board with New Appointment
Positive
Jan 27, 2025

Glow LifeTech Corp. has appointed David Côté, a seasoned leader in the cannabis retail industry, to its Board of Directors. Côté’s experience in scaling retail operations is expected to aid Glow’s expansion in the Canadian cannabis retail market, aligning with the company’s growth strategy. The appointment is accompanied by a grant of stock options, and coincides with internal changes where James Van Staveren steps down from the Audit Committee and Corporate Secretary roles, with Côté and CFO Josh Bald taking over those positions, respectively.

Glow LifeTech Expands MOD™ Drops to New Brunswick, Entering Atlantic Canada
Jan 13, 2025

Glow LifeTech has announced its expansion into the New Brunswick market with its MOD™ drops, marking its first entry into Atlantic Canada. This strategic move follows a successful year in Ontario and aligns with the company’s growth strategy to broaden its footprint across Canada, leveraging its proprietary technology to capture new market opportunities and drive growth.

Glow Lifetech Issues Stock Options to Team
Dec 27, 2024

Glow Lifetech Corp has granted 3,650,000 stock options to its officers and consultants, offering an opportunity for increased insider participation. The options come with a five-year exercise period, highlighting the company’s commitment to incentivizing its team amid its innovative focus on nutraceutical and cannabinoid-based products.

Glow Lifetech Finalizes Share Issuance and Debt Settlement
Dec 12, 2024

Glow Lifetech Corp. plans to issue 10 million shares to finalize its acquisition of Swiss Pharma, strengthening their strategic partnership in the cannabis and natural health sectors. Additionally, Glow intends to settle $510,470.44 in outstanding debt by issuing over 8 million shares, aiming to preserve cash for working capital.

Glow LifeTech Reports Strong Q3 2024 Results
Dec 2, 2024

Glow LifeTech Corp. reported a strong Q3 2024 with a 49% increase in revenue and 73% gross margins, reflecting its commitment to profitability and growth. The company improved its financial health through significant financing and debt settlement, enabling strategic investments. Glow also expanded its retail footprint in Ontario, positioning itself as a leader in the oils category.

Glow Lifetech Completes Funding and Debt Settlement
Nov 29, 2024

Glow Lifetech Corp. successfully completed a $900,000 private placement and settled $591,000 in debt by issuing shares, aimed at preserving cash for working capital. Insiders participated in the transaction, which was classified as a related party transaction, and Nova Capital Corp. increased its stake in the company. This strategic move reflects Glow Lifetech’s efforts to strengthen its financial standing.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 12, 2025